Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to Sell Rating by HC Wainwright

HC Wainwright lowered shares of Sarepta Therapeutics (NASDAQ:SRPT) from a neutral rating to a sell rating in a report issued on Monday morning, Marketbeat Ratings reports.

A number of other equities research analysts have also weighed in on the stock. Guggenheim dropped their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 7th. Scotiabank raised shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price objective on the stock in a report on Friday, June 6th. Piper Sandler lowered shares of Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $70.00 to $36.00 in a report on Monday. Finally, Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.35.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $20.94 on Monday. The firm’s fifty day simple moving average is $45.69 and its two-hundred day simple moving average is $85.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12-month low of $18.30 and a 12-month high of $173.25. The firm has a market capitalization of $2.06 billion, a P/E ratio of 16.75 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics’s quarterly revenue was up 80.2% compared to the same quarter last year. During the same period last year, the firm earned $0.73 earnings per share. Analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the last quarter. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $31,000. Ancora Advisors LLC raised its position in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.